Modulight Spotlights: LASER-SHARP RESEARCH – September 2023 Head & neck cancer is world’s sixth most common cancer, with increasing incidence and poor survival. A new study by P. Enzian & R. Rahmanzadeh at University of Lübeck, studied combining chemotherapy with photochemical internalization for more effective H&N cancer treatment in vitro. Photochemical internalization using photosensitizer fimaporfin, activated with Modulight’s ML6600 laser, was shown to increase drug’s efficacy by means of better drug delivery inside the cells. As a result, tumor cell death was achieved using 20-fold Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – August 2023 Interleukin 15 (IL-15) is promising candidate for cancer immunotherapy, since it is an inducer of differentiation and proliferation of killer T cells and NK cells. A new study by Fukushima et al. at NCI, published in Molecular Cancer Therapeutics, shows increase in therapeutic efficacy in vivo when IL15 was combined with photoimmunotherapy using ML7710 laser system. Intratumoral injection of IL-15 also boosted the immune responses against both the primary tumor as well as abscopal effect eradicating distant, untreated tumor.​ ​​ Read original publication Modulight Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – April 2023 Metastases remain the leading cause of cancer-related deaths worldwide. To combat this problem, Ruben V. Huis in ‘t Veld et al. combined immune checkpoint inhibitors with a light-activated virus-drug conjugate in their preclinical study. As published in Cancer Immunology, Immunotherapy journal, the combination was effective against metastatic tumors and in most cases even resulted in complete responses to therapy. ​​ Read original publication   Modulight is very happy to be supporting this research. We would like to deliver our Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – February 2023 The nomination for Laser-Sharp Research goes to Mäki-Mikola et al. at University of Helsinki for their development of a dynamic cell culturing platform for light-activation studies. The developed platform has a flow chamber connected to a peristaltic pump, which creates a flow that resembles the natural fluid flow at the cell surfaces. ML6500 laser was used to release calcein from liposomes to validate the suitability of the platform for light-triggered drug release. Compared to traditional static cell culture Continue reading →

Modulight Investor Contacts: Ulla Haapanen ulla.haapanen@modulight.com (408) 218-7960 Modulight Media Contacts: Zoe Ylöniemi zoe.yloniemi@modulight.com (408) 239-3488 Bausch + Lomb Investor Contacts: Arthur Shannon/Allison Ryan arthur.shannon@bausch.com allison.ryan@bausch.com (877) 354-3705 (toll free); (908) 927-0735 Bausch + Lomb Media Contacts: Lainie Keller/Kristy Marks lainie.keller@bausch.com kristy.marks@bausch.com (908) 927-1198; (908) 927-0683 Bausch + Lomb and Modulight Announce FDA Approval of ML6710i Photodynamic Laser for Use with Bausch + Lomb’s VISUDYNE® (Verteporfin for Injection) VAUGHAN, Ontario and TAMPERE, Finland, Feb. 1, 2023 – Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb”), a leading global Continue reading →

Modulight Spotlights: LASER-SHARP RESEARCH – December 2022 This month’s research spotlight goes to H. Wakiyama, H. Kobayashi, et al. at National Cancer Institute, USA. Their study, published in Cancer Immunology Research journal, looked into immunological mechanisms behind hyperprogressive disease. Immune checkpoint inhibitors, despite being a major success story in the field of cancer therapy, unfortunately lead to this rapid progression of cancer in some patients, for yet poorly understood reasons. To study this, the research team partially depleted cytotoxic T cells by photoimmunotherapy, using CD8-targeted Continue reading →